CPRX News and Press, Catalyst Pharmaceuticals Inc. From 03/16/22

Catalyst Pharmaceuticals (NASDAQ:CPRX) saw its Q4 2021 net income decline ~19% year over year even though revenue increased and beat estimates. Q4 net income stood at ~$9.3M ($0.09 per share, basic and diluted). Revenue increased ~24% year over year to ~$38.1M. Total operating costs and expen...

Catalyst Pharmaceuticals press release (NASDAQ:CPRX): Q4 GAAP EPS of $0.09 misses by $0.03. Revenue of $38.31M (+23.5% Y/Y) beats by $0.13M. Shares -0.13%. Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE® Orphan Drug Exclusivity. New Patent Issuances Strengthens FIRDAPSE ...

Total 2021 Revenues Increased Approximately 18% YoY to $141 Million Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE ® Orphan Drug Exclusivity New Patent Issuances Strengthens FIRDAPSE Long-Term Commercial Potential to 2034 Actively Pursuing Op...

IDEX, LEN, WSM, PD, CPRX, NBEV, SYN, OTCQX:MRMD, REI, OTCQX:TRSSF, ZTO, ASM, SMTC, GES, LGO, SMTS, BAK, LMB, LFT, EDR, ETON, IMV, PANL For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Wednesday's close

Catalyst Pharmaceuticals (NASDAQ:CPRX) is scheduled to announce Q4 earnings results on Wednesday, March 16th, after market close. The consensus EPS Estimate is $0.12 (+9.1% Y/Y) and the consensus Revenue Estimate is $38.18M (+23.1% Y/Y). Over the last 1 year, CPRX has beaten EPS estimates 100...

CORAL GABLES, Fla., March 11, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rar...

CORAL GABLES, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living wit...

CORAL GABLES, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living wit...

Catalyst Pharmaceuticals (CPRX +4.4%) said the U.S. Patent and Trademark Office will issue three patents related to its drug Firdapse, used to treat Lambert-Eaton myasthenic syndrome (LEMS) in the U.S. LEMS is a rare autoimmune disorder which causes miscommunication betwee...

Three New Patents Covering Additional Patient Amifampridine Metabolizer Types have been Allowed and will Issue in March 2022 Reinforces and Diversifies FIRDAPSE Long-Term Patent Portfolio Patent Portfolio Provides Intellectual Property Protection Until 2034 CORAL G...